KeTMo

Title

Low-dose KETamine as an adjunct to MOrphine for acute pain in the ED: a randomized, double-blinded, trial: KeTMo

Aim

To improve acute pain treatment in the ED, for both opioid tolerant and opioid naïve patients.

Methods

This is an investigator-initiated, randomized, parallel-grouped, double-blinded, superiority trial, investigating the combination of IV LDK and IV morphine versus IV morphine and placebo as regards to analgesic effect.

160 patients admitted to the ED with acute pain (NRS ≥5) will be enrolled, 80 with a prior use of opioids and 80 without a prior use of opioids.

Included patients will be randomized in a 1:1 ratio to either low dose ketamine or placebo as an adjunct to morphine.

Population

Adults, ≥ 18 years, admitted to ED with a pain full condition, NRS ≥5.

Perspectives

This is the first study to examine the effect of LDK as an adjunct to morphine in a general patient population in the ED with a prior use of opioids and to compare it with the effect for patients without a prior use of opioids.

This study could present a better pain treatment for patients with and without a prior use of opioids.

Primary investigator

Stine Fjendbo Galili

Sponsor

Professor Lone Nikolajsen

Registration numbers

EudraCT: 2021-005116-64   VEK: 1-10-72-334--21   LMST: 2021100973

Funder

Health Research Foundation of Central Denmark Region